Problem patents in innovator pharma Duncan 16 years ago In this recent European Biopharmaceutical Review article, Lee and Vandana analyse freedom to operate from the innovator perspective in the pharmaceutical and biotechnology areas. Here’s a link to the pdf – Think IP Strategy EBR Summer 2010 Please do let us know what you think. Share this: Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on Reddit (Opens in new window) Reddit Share on Pinterest (Opens in new window) Pinterest Share on Tumblr (Opens in new window) Tumblr Share on Threads (Opens in new window) Threads Share on WhatsApp (Opens in new window) WhatsApp The Mysterious Black BoxDateDecember 15, 2011In relation toInform and improve your IP StrategyWhere Manufacturing Goes So Follows InnovationDateAugust 23, 2012In relation toIncrease IP ValueOpen Innovation and IP StrategyDateDecember 20, 2007In relation toIP Management
